You are here

New Treatment For Dengue

Professor Subhash Vasudevan, Associate Professor Ooi Eng Eong from the Emerging Infectious Diseases Program and collaborators from Singapore General Hospital (SGH) have completed a clinical trial testing the efficacy of Celgosivir as an anti-dengue drug. With their findings, a US-based pharmaceutical company (60 Degrees Pharmaceuticals) has licensed the patent from Duke-NUS and will move this drug towards a clinical application through a full-scale Phase 2 clinical trial. This Phase 2 trial will be done as a multi-centre study involving several countries, including Singapore and Vietnam.

Search The Blog

Search

About Duke-NUS

Duke-NUS commits every gift to the most promising research and education programs to find cures, transform medicine and improve patients' lives.